Prestige Consumer Healthcare Inc. (PBH)
| Market Cap | 2.78B |
| Revenue (ttm) | 1.10B |
| Net Income (ttm) | 186.50M |
| Shares Out | 47.32M |
| EPS (ttm) | 3.79 |
| PE Ratio | 15.50 |
| Forward PE | 12.41 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 339,210 |
| Open | 59.01 |
| Previous Close | 58.30 |
| Day's Range | 57.90 - 59.15 |
| 52-Week Range | 51.24 - 89.37 |
| Beta | 0.47 |
| Analysts | Buy |
| Price Target | 75.33 (+28.22%) |
| Earnings Date | May 8, 2026 |
About PBH
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mo... [Read more]
Financial Performance
In fiscal year 2025, PBH's revenue was $1.14 billion, an increase of 1.10% compared to the previous year's $1.13 billion. Earnings were $214.61 million, an increase of 2.52%.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for PBH stock is "Buy." The 12-month stock price target is $75.33, which is an increase of 28.22% from the latest price.
News
Prestige Consumer Healthcare to Buy Breathe Right, Other Brands for $1.045 Billion
Prestige signed a deal to buy a portfolio of brands that includes the Breathe Right nasal strip from privately held Foundation Consumer Healthcare.
Prestige Consumer Healthcare Transcript: M&A announcement
The acquisition of a portfolio led by Breathe Right for $1.045 billion is expected to add 20% to revenue, be immediately accretive to margins and EPS, and double international presence, with limited synergies but strong long-term growth prospects and tax benefits.
Prestige Consumer Healthcare Announces Agreement to Acquire Breathe Right®, the Leader in Nasal Strips
TARRYTOWN, N.Y., March 20, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (the “Company” or “Prestige”) (NYSE: PBH) today announced that it has entered into a definitive agreement to acqui...
Prestige Consumer Healthcare Earnings Call Transcript: Q3 2026
Q3 revenue declined 2.4% year-over-year to $283.4 million, mainly due to Clear Eyes supply constraints, but strong free cash flow and e-commerce growth offset category softness. Fiscal 2026 guidance was narrowed, with EPS expected at $4.54 and free cash flow at $245 million or more.
Prestige Consumer Healthcare Inc. Reports Third Quarter and Year-to-Date Fiscal 2026 Results
TARRYTOWN, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and nine months ended December 31, 2025.
Prestige Consumer Healthcare Transcript: 28th Annual Needham Growth Conference Virtual
Resilient performance in 2025 was driven by a diversified portfolio, innovation-led brand building, and strong e-commerce growth. Clear Eyes supply recovery is underway, gross margins are set to improve, and capital allocation remains balanced with a focus on M&A and shareholder returns.
Prestige Consumer Healthcare Announces Fiscal 2026 Third Quarter Earnings Results Date and Participation in the ICR Conference
TARRYTOWN, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (the “Company” or “Prestige”) (NYSE: PBH) today announced it will issue its fiscal 2026 third quarter earnings rele...
Prestige Consumer Healthcare Earnings Call Transcript: Q2 2026
Q2 revenue and EPS exceeded expectations despite a 3.4% sales decline, driven by timing factors and strong e-commerce growth. Full-year guidance was reiterated, with improved Clear Eyes supply expected in the second half and continued robust free cash flow supporting share repurchases and M&A.
Prestige Consumer Healthcare Inc. Reports Second Quarter and First Half Fiscal 2026 Results
TARRYTOWN, N.Y., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its second quarter and first six months ended September 30, 2025.
Prestige Consumer Healthcare to Release Fiscal 2026 Second Quarter Earnings Results
TARRYTOWN, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2026 second quarter and first half earnings release on Thu...
Prestige Consumer Healthcare Transcript: Small-Cap Virtual Conference
A diversified consumer healthcare company outlined its three-pillar strategy focused on brand growth, financial strength, and capital allocation, achieving steady organic growth and strong free cash flow. Recent efforts address supply chain challenges in eye care, with ongoing investments in innovation, e-commerce, and M&A to drive long-term value.
Prestige Consumer Healthcare Transcript: Barclays 18th Annual Global Consumer Staples Conference 2025
Management highlighted strong brand connections, portfolio diversity, and a disciplined M&A strategy in a fragmented industry. E-commerce and innovation drive growth, with robust free cash flow supporting acquisitions and shareholder returns. Free cash flow outlook remains $245M+.
Prestige Consumer Healthcare to Present at the Barclays Global Consumer Staples Conference
TARRYTOWN, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced it will present at the Barclays Global Consumer Staples Conference on Thursday, Septemb...
Prestige Consumer Healthcare Earnings Call Transcript: Q1 2026
Q1 revenue declined 6.6% year-over-year due to eye care supply issues and retail order timing, but gross margin expanded and EPS rose 6%. The company expects supply recovery in the second half, maintains strong free cash flow guidance, and is acquiring Pillar5 to secure long-term eye care supply.
Prestige Consumer Healthcare Inc. Reports Fiscal 2026 First Quarter Results
Revenue of $249.5 million in Q1; decline driven by limited eye care supply Diluted EPS of $0.95 in Q1, up approximately 6% versus prior year Adjusted Diluted EPS of $0.90 Announces agreement to acquir...
Prestige Consumer Healthcare to Release Fiscal 2026 First Quarter Earnings Results
TARRYTOWN, N.Y., July 15, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2026 first quarter earnings release on Thursday, August 7,...
Medtech Products Inc. Issues Nationwide Recall of Little Remedies® Honey Cough Syrup Due to Microbial Contamination
TARRYTOWN, N.Y., June 17, 2025 (GLOBE NEWSWIRE) -- Medtech Products Inc., a Prestige Consumer Healthcare Inc. company (“Medtech” or “Company”), is voluntarily recalling five lots of Little Remedies® H...
Prestige Consumer Healthcare Transcript: 25th Annual Consumer Growth and E-Commerce Conference
The business delivered record sales and cash flow in fiscal 2025, with strong brand momentum and a robust innovation pipeline. Consumer shifts toward value channels and ongoing tariff impacts are being managed through cost savings and selective pricing. M&A remains a key growth lever, supported by strong free cash flow and disciplined capital allocation.
Prestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference
TARRYTOWN, N.Y., June 09, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will participate in a fireside chat at the Oppenheimer 25th Annual Consumer Grow...
Prestige Consumer Healthcare Earnings Call Transcript: Q4 2025
Record fiscal 2025 results featured revenue over $1.1B, 7% adjusted EPS growth, and strong free cash flow. Fiscal 2026 guidance anticipates continued revenue and margin expansion despite tariff and FX headwinds, with disciplined capital allocation and ongoing innovation supporting growth.
UPDATED: Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings
TARRYTOWN, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2025.
Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings
TARRYTOWN, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2025.
Prestige Consumer Healthcare to Release Fiscal 2025 Fourth Quarter and Year-End Earnings Results
TARRYTOWN, N.Y., April 10, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 fourth quarter and year-end earnings release on Thur...
Prestige Consumer Healthcare Earnings Call Transcript: Q3 2025
Record Q3 sales and EPS were driven by strong international and North American growth, with robust free cash flow and improved leverage. Fiscal 2025 guidance was raised for EPS, while free cash flow and revenue outlooks remain strong.
Prestige Consumer Healthcare Inc. Reports Record Third Quarter Results and Raises Full-Year Earnings Outlook
TARRYTOWN, N.Y., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and first nine months ended December 31, 2024.